CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (CBPO): 5 pipeline candidates · ~29 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
29.1 months
D/E 0.10 · 1% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$161.8M
Quarterly Burn
$85.1M
Runway
29.1 mo
Revenue
$503.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| human rabies immunoglobulin | Phase 2 |
| rabies vaccine | Phase 2 |
| recombinant human rabies virus monoclonal antibody | Phase 2 |
| sibp-a10 | Phase 1 |
| sibp-r002 | Phase 1 |
Frequently asked questions
How many drug candidates are in CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.'s pipeline?
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (CBPO) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.'s lead drug candidate?
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.'s most advanced tracked candidate is human rabies immunoglobulin (Phase 2) for Rabies (Healthy Volunteers).
What is CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. has approximately 29.1 months of cash runway.
Get the full picture on CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.